International Journal of Ophthalmology and Optometry

ISSN Print: 2664-8547
ISSN Online: 2664-8555
IJOO 2025; 7(1): 33-42
www.ophthajournal.com
Received: 12-02-2025
Accepted: 15-03-2025

Mohammed Abbas Abed
Department of Ophthalmology, Tikrit University, Collage of medicine, Tikrit, Iraq

Corresponding Author:
Mohammed Abbas Abed
Department of Ophthalmology, Tikrit University, Collage of medicine, Tikrit, Iraq

The role of gut microbiome in ocular diseases: A systematic review

Mohammed Abbas Abed

DOI: https://www.doi.org/10.33545/26648547.2025.v7.i1a.44

Abstract
The gastrointestinal tract contains a complex bacterial community known as the gut microbiome which deeply affects systemic health alongside immunological function and inflammation. The gut microbiota shows potential to significantly affect the development of dry eye disease (DED) and age-related macular degeneration (AMD) and diabetic retinopathy and uveitis. Different ocular diseases emerge from gut dysbiosis through systemic inflammation together with immunological regulation and oxidative stress. Short-chain fatty acids (SCFAs) derived from microbial metabolism show potential to trigger retinal degeneration in AMD patients while DED patients experience increased ocular surface inflammation due to changes in their gut microbiota composition. The retinal vascular damage in diabetic retinopathy worsens when gut microbial diversity changes because it leads to increased systemic inflammation and endothelial dysfunction. The insufficient development of gut flora in autoimmune uveitis leads to worsened immunological control and intensified ocular inflammation. Research on dietary modifications and prebiotics and probiotics as gut microbiota restoration treatments through the gut-eye axis shows promise to develop new therapeutic strategies for ocular disease management. The unknown mechanisms between gut microbiota and ocular health demonstrate potential for new ophthalmology treatments according to current research findings. Additional research needs to establish these relationships better to develop better treatment approaches for ocular diseases that stem from gut dysbiosis.

Keywords: Gut microbiome, ocular diseases, dysbiosis, dry eye disease, diabetic retinopathy

Introduction
Medical research now focuses on the human gut microbiome because of its significant effects on human health (Figure 1). The microbial population plays an essential role in multiple physiological functions that include metabolism and immune system operation and pathogen protection [1]. The essential role of gut bacteria beyond the gastrointestinal system has become more apparent through increasing research evidence during the past ten years. Scientists now study the gut microbiome-ocular health connection because it shows how stomach microbial balance affects different eye diseases [2].

Health services worldwide face significant challenges from diabetic retinopathy and uveitis and dry eye disease and age-related macular degeneration. The available treatment options for these diseases remain limited when it comes to addressing root causes including inflammation and immune system dysfunctions [3]. Research indicates that the gut microbiome has the potential to influence systemic inflammation and immunological responses which may lead to various eye diseases. The relationship between gut flora imbalance known as dysbiosis has been found to contribute to several inflammatory diseases which might either trigger or worsen ocular disorders [4].

The gut-eye axis has gained increasing attention after its initial use to describe the two-way communication between gut microbiota and ocular tissues. Multiple studies have investigated how immunological responses together with inflammatory cytokines and microbial metabolites from the gut affect ocular health [5]. Short-chain fatty acids (SCFAs) and other microbial metabolites possess anti-inflammatory properties that could serve to either prevent or reduce ocular inflammation. The gut microbiota plays an essential role in the development of ocular diseases especially those with chronic inflammation including AMD and

diabetic retinopathy [6]. This review will deeply analyze the role of gut flora in ocular diseases by focusing on its possible mechanisms and introducing the concept of the gut-eye axis.



Fig 1: Human microbiomes from different organs

The Gut-Eye Axis: Understanding the Communication Pathway

Research on the two-way interaction between the health of the eyes and the bacteria in the gut is witnessing great increase under the "gut-eye axis" (Figure 2). This concept is based on the mounting evidence that the gut flora is not only important for the digestive tract but also for a variety of systemic diseases, including problems with vision. Improved knowledge of the relationship between the stomach and the eyes might help to design creative treatment approaches for ocular diseases [7].

Gut Microbiome Roles in Immune Function

Many immunological reactions in the body are brought about by the gut bacteria. Particularly gut-associated lymphoid tissue (GALT), the gastrointestinal tract comprises around 70-80% of the human immune system. By means of interactions with immune cells, the gut flora starts defense mechanisms against dangerous infections and fosters tolerance to helpful bacteria. Beyond the stomach, this immune-modulating action of the gut bacteria fosters systemic immunity, which affects far-off organs like the eyes [8].

Many ocular disorders, including dry eye disease, age-related macular degeneration (AMD), diabetic retinopathy, and uveitis, progress and development of which depend critically on the immune system. Within the framework of the gut-eye axis, gut-generated immunological signals and inflammatory mediators can pass via the bloodstream and affect ocular tissues. For example, some microbial metabolites such as short-chain fatty acids (SCFAs) are able to control immune cell activity and hence reduce inflammation. On the other hand, dysbiosis-imbalance in gut flora may cause systemic inflammation that can have a domino effect on the eyes and contribute to ocular disorders [9].



Fig 2: The gut-eye axis in retinal disease & health

Microbial Metabolites Role in Ocular Health

Through the synthesis of microbial metabolites, particularly short-chain fatty acids (SCFAs), including acetate, propionate, and butyrate, one of the main routes via which the gut microbiome influences ocular health is Maintaining gut health depends much on SCFAs, which are byproducts of the fermenting food fibers by gut bacteria. Still, their impact goes well beyond the stomach; it affects many organs, including the eyes [10].

SCFAs can change immune response and have anti-inflammatory effects. These metabolites can affect immune cells-including those in the eye-that flow across the body when absorbed into the bloodstream. For instance, SCFAs have been demonstrated to lower the synthesis of pro-inflammatory cytokines, linked to several ocular disorders including uveitis and dry eye disease. Reducing inflammation and encouraging a healthy immune response helps SCFAs guard ocular structures from injury [11].

Moreover, SCFAs can improve the integrity of the blood-retinal barrier, therefore stopping dangerous compounds from reaching the retina. In diseases like diabetic retinopathy, when the blood-retinal barrier is weakened and causes vascular leakage and retinal damage, this is especially critical. Preserving the generation of these beneficial substances and protection of the eyes from inflammatory damage thus rely on a proper gut flora [12].

The Impact of Dysbiosis on Ocular Diseases

The condition known as dysbiosis or gut flora imbalance produces significant effects on eye health by generating systematic inflammation. The growth of harmful bacteria leads to the production of inflammatory cytokines and immune mediators which enter circulation to affect distant organs including the eyes [13].

The ocular surface suffers damage from dry eye disease (DED) when the gut microbiome becomes imbalanced. The condition frequently develops in people with gastrointestinal issues and inflammatory cytokines such as tumor necrosis factor-alpha (TNF-α) and interleukin-6 (IL-6) lead to ocular surface inflammation and modified tear production. The inflammatory response creates a chain reaction that worsens disease symptoms including eye irritation together with visual distortions and discomfort [14].

The supposed damage to retinal cells in age-related macular degeneration (AMD) occurs through gut dysbiosis which intensifies chronic inflammation and cellular oxidative stress. The disruption of gut bacteria leads to increased pro-inflammatory cytokines which damage retinal cells and accelerate AMD progression. Systematic inflammation and endothelial dysfunction in diabetic retinopathy worsen due to dysbiosis which results in retinal vascular anomalies [15].

The Impact of the Gut-Brain-Eye Connect

The gut microbiota's effects on ocular health operate through its brain-mediated mechanisms to create a comprehensive gut-brain-eye axis. Through the vagus nerve, the stomach sends signals to the central nervous system which regulates body-wide inflammatory reactions including those in the ocular region. The gut microbiome regulates brain inflammation which leads to prevention of eye diseases that stem from immunological dysfunction [16].

The gut-brain-eye link could clarify the relationship between some ocular diseases, particularly those with autoimmune or inflammatory traits, and other systemic conditions, including depression or stress-related disorders, which might also involve changes in gut microbiota composition [17].

Gut Microbiome and Dry Eye Disease (DED)

A chronic disorder brought on by inadequate or poor-quality tears, dry eye disease (DED) causes ocular surface damage and inflammation. It is distinguished from others by dryness, burning, itching, redness, irritation, and impaired vision [18]. Among the many causes of DED are environmental and physiological ones include aging, hormonal changes, autoimmune diseases, and environmental stresses. Recent studies, however, have shown a fascinating link between the gut microbiota and DED wherein microbial imbalances in the stomach might have a major effect on the pathophysiology of this disease [19].

Comprising billions of bacteria, fungus, viruses, and archaea, the gut microbiome is essential for preserving general health especially in relation to immune response modulation and inflammation management. New research evidence suggests that gut bacterial patterns could influence immune system responses and systemic inflammation which both play roles in developing ocular diseases including DED [20].

The Role of the Gut Microbiome in Immune Regulation

The gut microbiota regulates immune responses through its control of immunological functions which represents its primary mechanism of supporting DED. The gut contains vital immune structures together with GALT which functions as a major component of the immune system. The training area of GALT enables immune cells to identify between pathogens and beneficial bacteria. The training process enables equilibrium of immunity while reducing hyperactive immune responses [21].

The gut flora serves as the main controller of immune response modulation throughout the entire body. An imbalance in gut flora known as dysbiosis leads to an overactive immune system. The spread of dysbiosis to other bodily areas including the eyes results in elevated systemic inflammation together with activated immune systems. Higher immunological activity in DED leads to ocular surface inflammation which reduces tear production and causes the dryness and discomfort symptoms of the disease [22].

Those with intestinal dysbiosis particularly have raised levels of pro-inflammatory cytokines like TNF-α and IL-6. These cytokines pass via the blood to the ocular surface, where they might damage the tear-producing glands, therefore lowering tear production and aggravating DED symptoms. Moreover, gut microbiome-derived inflammatory mediators may change the operation of the conjunctival and lacrimal glands, thereby promoting the chronic inflammation seen in DED [23].

Short-Chain Fatty Acids (SCFAs) Role in DED

Systemic health modification by gut microbiota depends on the production of short-chain fatty acids. The breakdown of dietary fiber by gut bacteria produces three main SCFAs which are acetate, propionate and butyrate. These metabolites enter circulation to influence multiple organs including the eyes [24].

Particularly crucial for the maintenance of epithelial cells in many organs, including the ocular surface, SCFAs are known to exert anti-inflammatory effects. Through the stimulation of the formation of regulatory T cells (Tregs), which are essential in lowering overly strong immune responses and

preserving tolerance to self-antigens, SCFAs may help control the immune system. By controlling immunological responses and hence lowering the production of pro-inflammatory cytokines, SCFAs might help lower ocular surface inflammation in DED [25].

By keeping inflammatory cells and mediators from invading the ocular tissues, SCFAs also help to preserve the blood-ocular barrier. Protection of the delicate components of the eye from damaging chemicals and immune cells that might otherwise aggravate inflammation in diseases like DED [26] depends on a healthy blood-ocular barrier.

Dysbiosis and Its Impact on Ocular Surface Inflammation

Many inflammatory diseases, including DED, have been linked to dysbiosis-that is, an imbalance of gut flora. Harmful bacteria or pathogenic microorganisms may predominate in the intestinal settings of dysbiosis patients, leading to an excess of pro-inflammatory cytokines generation. These inflammatory markers may reach far-off organs like the eyes via the circulation, where they increase inflammation and assist to breakdown the ocular surface [27].

Studies have shown that patients with DED sometimes show different gut flora than those of healthy people. For instance, studies show that the variety of gut bacteria is declining while pro-inflammatory bacterial species, such Firmicutes, are overrepresented and beneficial bacteria like Bacteroidetes [28] are declining as well. It is hypothesized that this microbial imbalance fuels the systematic inflammation seen in DED sufferers. Harmful and beneficial bacteria have an imbalance that causes an overproduction of cytokines involving IL-6 and TNF-α, which are well-known to aggravate inflammation and immunological malfunction in the eyes [29].

Furthermore, influencing the autonomic nerve system, which is essential for tear generation, is gut dysbiosis. Through the vagus nerve, the gut microbiome affects the central nervous system; dysbiosis could cause disturbances in the communication channels meant to control tear production. By lowering the generation of enough tears to maintain the ocular surface moist and protected, this could aggravate DED symptoms even more [30].

Potential Therapeutic Approaches

Given the important part the gut microbiome plays in the development and course of DED, changing the microbiome offers a fascinating therapeutic possibility for controlling this disorder. Two possible treatments under examination in clinical research are prebiotics and probiotics [31].

- Probiotics are living, helpful bacteria that, when ingested, can bring the gut flora back into equilibrium. Probiotics may help lower systemic inflammation and enhance immunological control; some researchers have indicated. Probiotics might help to lower ocular surface inflammation in DED by so controlling the hyperactive immune response brought on by dysbiosis [32].
- Dietary fiber and other non-digestible food components known as prebiotics help healthy gut bacteria to proliferate. By helping the gut's microbial equilibrium to be restored, prebiotics may boost immune system performance and lower systemic inflammation, therefore helping to prevent DED [33].
- Dietary Interventions: The gut microbiome is much impacted by diet. A diet high in antioxidants, fiber, and anti-inflammatory drugs could help to maintain a good gut flora and lower inflammation in the eyes as well as in the gut. Particularly omega-3 fatty acids in fish oil have anti-inflammatory effects and might help DED patients produce more tears [34].
- Fecal Microbiota Transplantation (FMT) is currently experimental but entails the transfer of healthy gut flora from a donor to a recipient therefore restoring equilibrium in the recipient's microbiome. This method could be investigated as a future DED treatment, especially in cases when conventional treatments have failed [35].

Role of Gut Microbiome in Age-Related Macular Degeneration (AMD)

Mostly affecting the macula, the core section of the retina in charge of sharp and detailed vision, age-related macular degeneration (AMD) is the main cause of visual loss among older persons. Progressive degeneration of the retinal cells, especially in the retinal pigment epithelium (RPE), defines AMD and can cause extreme vision loss or blindness. Although oxidative stress, genetic elements, and vascular alterations are well-known causes of AMD, new studies have started to investigate how the gut microbiome shapes the course of this disorder [36].

All of which are linked in AMD pathophysiology, the gut microbiome significantly controls systemic inflammation, immunological responses, and oxidative stress. An imbalance in the gut flora known as dysbiosis can cause altered immunological responses and overgeneration of pro-inflammatory cytokines. These systemic changes can impact far-off organs including the eyes. More especially, the gut-derived inflammatory indicators can aggravate retinal inflammation and macular degeneration, hence hastening the course of AMD. Furthermore, several microbial metabolites, notably short-chain fatty acids (SCFAs), have anti-inflammatory and neuroprotective properties that might assist to reduce retinal damage and AMD-related inflammation [37].

Recent research indicates that those with AMD can show different alterations in their gut flora, including a decrease in helpful bacterial species and an increase in inflammatory cells. Both retinal inflammation and oxidative damage, major causes of AMD, may be worsened by these microbial changes. Furthermore, helping to manage the inflammatory milieu in the retina could be the effect of the gut microbiome on the blood-brain barrier and its capacity to affect the balance of immune cells such as regulatory T cells (Tregs).

Gut Microbiome and Diabetic Retinopathy

A severe side effect of diabetes, diabetic retinopathy (DR) compromises the retina and, if unchecked, may cause visual loss. Long-term high blood sugar levels are mostly responsible for it since they might compromise the blood vessels in the retina, which causes leakage, bleeding, and finally vision impairment. Growing interest in knowing how systematic elements, particularly the gut microbiota, affect the development and progression of diabetic retinopathy as the prevalence of diabetes keeps increasing worldwide [39].

Regulating immunological responses, inflammation, and metabolic processes depends on the gut microbiota in great part. Many systemic disorders, including diabetes, have been related to an imbalance in gut flora sometimes referred to as dysbiosis. Dysbiosis can aggravate systemic inflammation and cause insulin resistance in diabetic individuals, therefore aggravating the vascular damage in the retina. Key causes of diabetic retinopathy are chronic inflammation and raised pro-

inflammatory cytokine levels including TNF-α and IL-6. Both characteristics of diabetic retinopathy, these cytokines can raise the permeability of retinal blood vessels and encourage the creation of new, aberrant blood vessels (neovascularization) [40].

Moreover, the gut microbiota affects the way nutrients are metabolized and generates metabolites such as short-chain fatty acids (SCFAs), known to have anti-inflammatory and preventive properties. A good gut flora encourages the synthesis of SCFAs, which lower inflammation and guard against endothelial dysfunction-the inability of blood vessels to operate as they should-a main characteristic of diabetic retinopathy. But dysbiosis can lower SCFA generation, which would create a more pro-inflammatory environment and aggravate retinal injury [41].

Studies show that diabetic retinopathy patients who keep normal gut bacteria levels experience reduced inflammation and better blood vessel function. Research into probiotics, prebiotics and dietary interventions for gut health shows promise in lowering inflammation and improving metabolic control in diabetic patients and may offer new therapeutic approaches to prevent or slow diabetic retinopathy development [42].

Gut Microbiome in Uveitis: Immune Dysregulation and Inflammation: Affecting the uveal tract of the eye including the iris, ciliary body, and choroid uveitis is an inflammatory disorder. Untreated, it can cause notable visual loss. Usually connected to immune system dysregulation where the body's immune response targets its own tissues the disorder is although trauma, autoimmune illnesses, and infections are among the several causes of uveitis (Figure 3), recent studies have started to show the possible influence of the gut microbiota in the onset and course of the condition [43].

Maintaining immunological tolerance and avoiding autoimmune reactions depend on the immune system being regulated by the gut microbiota, which also is fundamental. Key component of the body's immune system, gut-associated lymphoid tissue (GALT) interacts with gut bacteria to control immunological reactions. By guiding immune cells toward tolerance to benign antigens and starting defensive systems against infections, the microbiome aids in their education. But when the gut microbiota is thrown off a disease known as dysbiosis an excessive immune response can result, causing systemic inflammation that might compromise several organs, including the eyes [44].

The immune response becomes impaired by gut microbiome dysbiosis in a uveitis environment which worsens ocular inflammation. Scientific research indicates that changes in gut bacteria composition trigger body-wide inflammatory responses which generate more immune mediators especially pro-inflammatory cytokines. The inflammatory signals produced by the immune cells travel to the eyes which leads them to attack ocular tissues and create the inflammation known as uveitis. Individuals with gut dysbiosis tend to have elevated levels of TNF-α and IL-17 pro-inflammatory cytokines that are associated with uveitis [45].

The development of uveitis depends heavily on how gut bacteria affect the blood-retinal barrier which functions as a defensive layer against dangerous chemicals that reach the retina. The breakdown of the blood-retinal barrier because of dysbiosis exposes the eye to immune cell invasion and inflammation. The breakdown of ocular barrier function leads to accelerated uveitis onset resulting in persistent inflammation together with tissue damage and vision deterioration [46].

The establishment of immunological homeostasis relies heavily on microbial metabolites specifically short-chain fatty acids (SCFAs) as new research demonstrates. The breakdown of dietary fibers through intestinal microbial activity produces short-chain fatty acids which display anti-inflammatory properties. Short-chain fatty acids maintain control over immune cells by regulating the production of regulatory T cells (Tregs) that function to limit excessive immunological reactions. Strong gut flora can produce more SCFAs which create an anti-inflammatory setting that might help stop uveitis development. Dysbiosis leads to decreased SCFA manufacturing which worsens inflammation while elevating the chances of immune-mediated diseases such as uveitis [47].

Research linking the gut microbiome to immune control demonstrates that altering the gut flora might lead to uveitis treatments. Research has been conducted on live beneficial bacteria known as probiotics to study their effects on restoring balance to the gut flora and decreasing systemic inflammation. The growth of beneficial bacteria is enhanced by prebiotics which simultaneously help restore microbial diversity and strengthen the immune response. The prevention and reduction of uveitis symptoms can be achieved through dietary interventions that enhance fiber consumption and decrease intake of processed foods to support a balanced gut microbiota [48].



Fig 3: The role of the gut microbiome in eye diseases

Therapeutic Potential of Probiotics and Prebiotics in Ocular Diseases: The gut flora determines many aspects of general health by regulating the immune system and inflammation and systemic illness response. Research now demonstrates that the gut microbiome plays a major role in eye health by affecting conditions such as uveitis and diabetic retinopathy (DR) and age-related macular degeneration (AMD) and dry eye disease (DED). The gut microbiome modification techniques prebiotics and probiotics have gained substantial interest as potential therapeutic tools for managing ocular disorders [49].

Probiotics and Their Role in Ocular Diseases

Utilized in sufficient quantities, living bacteria known as probiotics help the host be healthier. Especially in a state of dysbiosis or disturbance of the gut microbiome, these helpful bacteria can help bring the gut flora back into equilibrium.

Probiotics have therapeutic potential because they can lower systemic inflammation, change immunological responses, and enhance gut health all of which are vital in controlling ocular illnesses [50].

Research indicates that probiotics have the ability to reduce ocular surface inflammation which is a primary aspect of dry eye disease (DED) while the known aggravation of eye inflammation by suggests probiotics can control the immune system response and decrease pro-inflammatory cytokines such as TNF-α and IL-6. The ocular surface inflammatory reactions can be controlled by probiotics through immunological tolerance promotion which leads to tear production increase and DED discomfort reduction [51].

Probiotics have shown promise in reducing systemic inflammation and improving vascular health for conditions such as diabetic retinopathy (DR) and age-related macular degeneration (AMD) which result from chronic inflammation and oxidative stress. Probiotics modify gut immune system function which leads to systemic immune response changes and potential retinal inflammation reduction for slowing the progression of these degenerative diseases [52].

Probiotics may help control the immune system in uveitis, an autoimmune-driven inflammatory disorder affecting the eye, therefore preventing too strong inflammation. Probiotics may help to lower ocular inflammation and stop the aggravation of uveitis symptoms by increasing the generation of regulatory T cells (Tregs) and so lowering the activation of pro-inflammatory Th17 cells [53].

Prebiotics and Their Role in Ocular Diseases

Non-digestible dietary components called prebiotics help good bacteria in the gut flourish and be active. Unlike probiotics, which bring live microorganisms into the system, prebiotics support a varied and balanced microbiome by helping to activate the growth and activity of current beneficial bacteria [54].

Short-chain fatty acids (SCFAs) including acetate, propionate, and butyrate all with anti-inflammatory effects have been found to be produced in response to prebiotics. The production of SCFAs stands as a critical factor for both immunological homeostasis and maintaining a healthy gut environment. The anti-inflammatory effects of SCFAs lower pro-inflammatory cytokine synthesis to help treat dry eye disease (DED) and age-related macular degeneration (AMD) and reduce systemic inflammation. The ocular surface experiences decreased inflammatory stress through prebiotic-induced SCFA elevation which leads to increased tear production and reduced retinal damage risk [55].

The blood-ocular barrier maintains its integrity through prebiotics which provides essential protection to the retina and other eye regions from harmful substances. The barrier receives improvement through prebiotics because they establish a healthy gut microbiota that stops inflammatory chemicals and immune cells from entering ocular tissues [56]. Prebiotics might help control the gut microbiome in diabetic retinopathy (DR), therefore lowering systemically inflammation and enhancing glucose metabolism. Improving gut health and lowering inflammation could be a good way to stop or slow down the advancement of diabetic retinopathy since diabetes is the main risk factor for DR [57].

Mechanisms of Action: How Probiotics and Prebiotics Work: Prebiotics and probiotics both act therapeuticize via different channels:

- The combination of prebiotics and probiotics helps manage immunological responses through enhanced regulatory T cell activity which reduces excessive immune activation. The promotion of immunological tolerance prevents the immune system from attacking healthy tissues such as the ocular surface together with the retina and uveal tract [58].
- Both probiotics and prebiotics lower the synthesis of pro-inflammatory cytokines (e.g., TNF-α, IL-6, IL-17), which are linked in the inflammatory processes of ocular disorders. This anti-inflammatory action shields the eyes from inflammatory damage under disorders including DED, AMD, and uveitis [59].
- Improvement of Gut Barrier Function: Prebiotics and probiotics help to preserve the integrity of the gut mucosal barrier, therefore stopping the translocation of dangerous bacteria and toxins that would aggravate systemic inflammation. Maintaining general immune system homeostasis and lowering eye inflammation depend on this action [60].
- Short-Chain Fatty Acids (SCFAs) which are produced by gut bacterial fermentation of fiber are responsible for reducing inflammation and strengthening the immune system. Prebiotics help to reduce inflammation by encouraging the expansion of SCFA producing bacteria, therefore improving eye health [61].

Potential for Clinical Application in Ocular Diseases

The therapeutic application of probiotics and prebiotics for ocular diseases remains in its early stages of research despite initial promising findings. Researchers conduct ongoing clinical trials to study how probiotics and prebiotics affect dry eye disease (DED), age-related macular degeneration (AMD), diabetic retinopathy (DR) and uveitis while preliminary findings indicate that gut microbiome modification can lead to reduced inflammation and enhanced immune responses and delayed disease progression [62].

Probiotics have been found, for instance, to improve ocular surface health, lower dry eye symptoms, and increase tear generation in people with DED. Future treatments in AMD and DR could find great promise to lower retinal inflammation and enhance vascular health by means of microbiome regulation. Driven by autoimmune processes, uveitis may also gain from gut microbiome modification to control immune responses and lower ocular inflammation [63].

Future Directions: Microbiome-Based Therapies for Ocular Health: The gut microbiome consisting of complex microbial communities within the gastrointestinal tract has recently become a focus of interest because it strongly affects general health through immunological modulation and inflammatory control and metabolic processes. Recent data demonstrates that the gut microbiome plays a vital role in eye health by affecting uveitis and three other eye conditions including diabetic retinopathy (DR), dry eye disease (DED) and age-related macular degeneration (AMD). The growing understanding of gut-eye linkages reveals promising potential for microbiota-based treatments to prevent and treat ocular disorders [64].

Microbiome Modulation through Probiotics and Prebiotics: Using prebiotics and probiotics is one of the most fascinating and easily available microbiome-based treatment modalities. While prebiotics are non-digestible food elements that selectively stimulate the growth of helpful bacteria [65], probiotics are live beneficial microorganisms that, in

sufficient quantities, can restore balance to the gut microbiome and hence confer health benefits.

Systemic inflammation which plays a major role in various eye diseases shows potential to be reduced through probiotic treatment. Probiotics have shown potential to treat conditions such as dry eye disease and diabetic retinopathy and uveitis through their ability to regulate immune responses and stimulate anti-inflammatory cytokine production. The lacrimal glands receive modified immune cell activity through probiotic treatment which enables dry eye patients to produce additional tears. Prebiotics enable beneficial gut bacteria to grow which leads to increased short-chain fatty acid (SCFAs) production with anti-inflammatory properties that protect the retina and potentially reduce ocular surface inflammation [66].

Therapies combining probiotics and prebiotics catered to individual microbiomes may offer more customized, efficient therapy choices for eye illnesses going forward. The most efficient strains of probiotics and the best prebiotics for particular ocular diseases still need further clinical trials and research [67].

Fecal Microbiota Transplantation (FMT)

A novel and creative treatment called fecal microbiota transplantation (FMT) entails moving fecal matter from a healthy donor to a recipient with an imbalance of the microbiome. FMT seeks to restore microbial diversity and enhance gut health. Though FMT is mostly utilized in treating disorders like Clostridium difficile infections, new research has revealed that FMT could have possible uses in treating systemic diseases caused by dysbiosis, including autoimmune and inflammatory diseases [68].

FMT may be investigated as a future therapeutic choice for restoring the balance of gut bacteria and reducing ocular inflammation given the mounting data connecting the gut microbiome to ocular illnesses including uveitis. Where immunological dysregulation is fundamental to disease development, this medication could help control systemic inflammation, lower pro-inflammatory cytokines, and perhaps halt the course of illnesses like uveitis [69]. Although FMT is presently being tested for eye problems, ongoing research into its capacity to modulate the immune system and restore microbial balance may lead to innovative treatments in the future.

Diet and Nutritional Interventions

The human gut microbiota responds efficiently to dietary changes which leads to better ocular health. A diet containing fiber together with polyphenols and omega-3 fatty acids supports microbiome health through the growth of beneficial bacterial populations. Short-chain fatty acids (SCFAs) emerge from these dietary components while displaying anti-inflammatory properties that help reduce ocular inflammation in AMD and dry eye syndrome [70].

The omega-3 fatty acids found in fish oil demonstrate anti-inflammatory properties which help reduce systemic inflammation while generating anti-inflammatory molecules that ease dry eye disease symptoms. Polyphenol-containing foods including fruits vegetables and whole grains can strengthen the immune system while supporting healthy gut microbiota [71].

The assessment of individual microbiota patterns allows healthcare providers to create personalized nutritional plans which help protect eye health and prevent or treat future eye problems. The combination of dietary changes with prebiotics and probiotics and other microbiome-focused treatments creates more complete and effective treatments for uveitis and diabetic retinopathy and age-related macular degeneration (AMD) [72].

Targeted Microbiome Therapies for Specific Ocular Diseases: As the role of the gut-eye axis remains unclear, it is possible that specific microbiome treatments could be developed for different ocular disorders in future as the complexity of the interrelationship is better understood. For example, for dry eye disease, treatments that aim at promoting a healthy gut microbiome may enhance tear production and reduce inflammation of the ocular surface. Microbial based therapies may potentially help in the improvement of retinal degeneration, vascular health and reduction in systemic inflammation in diseases such as AMD and diabetic retinopathy [73].

Microbial metabolites like SCFAs may find application as a therapy for eye conditions. Made by helpful gut bacteria, SCFAs have been demonstrated to have anti-inflammatory properties and alter immune system response. Delivering these metabolites straight to the eye or boosting their synthesis by dietary treatments, probiotics, or prebiotics could help reduce the inflammation and oxidative stress causing disorders including AMD and DR [74].

Microbiome-Based Drug Development

The development of microbiome-based treatments for ocular diseases appears certain as our understanding of gut microbiota in eye health continues to grow. The medications would modify the gut microbiome through bacterial addition or microbial chemical synthesis enhancement or through bacterial elimination. Bacteriophage therapy represents a promising approach to manage microbial imbalances that worsen eye disorders by using viruses that specifically target pathogenic bacteria [75].

Apart from microbiome-based medications, topical probiotics or treatments delivering beneficial bacteria straight to the ocular surface could become a choice for treating ocular disorders such dry eye disease or uveitis. These treatments could restore a balanced microbiota in the ocular environment, therefore lowering inflammation and fostering healing [76].

Personalized Microbiome Medicine

The development of microbiome-based ocular health treatments will probably be influenced by personalized medicine which uses individual microbiome profiles to create treatment plans. Metagenomics and microbiome sequencing advancements will help physicians understand individual microbiomes and their effects on eye health. Healthcare professionals can enhance treatment results and minimize adverse effects by detecting particular microbial imbalances to use appropriate probiotic strains or dietary modifications as targeted interventions [77].

The microbiome-based personalized approach enables healthcare professionals to detect patients who face higher risks of developing ocular disorders so they can start preventive measures early. The customized treatment approach shows promise to deliver better results because it specifically targets microbial imbalances which worsen disease progression [78].

Conclusion

The gut microbiota plays a vital role in maintaining eye health because scientists now understand its essential part in the development of uveitis and three other eye conditions including age-related macular degeneration and diabetic retinopathy and dry eye syndrome. Through the gut-eye axis, dysbiosis creates a complex relationship that activates immune responses and systemic inflammation which results in ocular inflammation and damage. The combination of probiotics with prebiotics and dietary interventions and microbiome-based therapies shows promise to restore microbial balance while reducing inflammation for better ocular health. Additional clinical research studies are needed to confirm the effectiveness of these treatments for ocular diseases. The development of personalized microbiome-based treatments for ocular diseases shows promise to transform eye care because research into gut microbiota continues to grow thus providing a new non-invasive method to protect eye health.

References

1. Aggarwal N, Kitano S, Puah GRY, Kittelmann S, Hwang IY, Chang MW. Microbiome and human health: Current understanding, engineering, and enabling technologies. Chem Rev. 2023;123(1):31-72. https://doi.org/10.1021/acs.chemrev.2c00431
2. Hooper LV, Gordon JI. Commensal host-bacterial relationships in the gut. Science. 2001;292(5519):1115-8. https://doi.org/10.1126/science.1058709
3. Klein R, Klein BE. The prevalence of age-related eye diseases and visual impairment in aging: Current estimates. Invest Ophthalmol Vis Sci. 2013;54(14):ORSF5-13. https://doi.org/10.1167/iovs.13-12789
4. Varma R, Ying-Lai M, Klein R, Azen SP; Los Angeles Latino Eye Study Group. Prevalence and risk indicators of visual impairment and blindness in Latinos: The Los Angeles Latino Eye Study. Ophthalmology. 2004;111(6):1132-40. https://doi.org/10.1016/j.ophtha.2003.11.027
5. Nguyen Y, Rudd Zhong Manis J, Ronczkowski NM, Bui T, Oxenrider A, Jadeja RN, Thounaojam MC. Unveiling the gut-eye axis: How microbial metabolites influence ocular health and disease. Front Med. 2024;11:1377186. https://doi.org/10.3389/fmed.2024.1377186
6. Hou K, Wu ZX, Chen XY, Wang JQ, Zhang D, Xiao C, *et al.* Microbiota in health and diseases. Signal Transduct Target Ther. 2022;7:135. https://doi.org/10.1038/s41392-022-00974-4
7. Zhang H, Mo Y. The gut-retina axis: A new perspective in the prevention and treatment of diabetic retinopathy. Front Endocrinol. 2023;14:1205846. https://doi.org/10.3389/fendo.2023.1205846
8. Wiertsema SP, van Bergenhenegouwen J, Garssen J, Knippels LMJ. The interplay between the gut microbiome and the immune system in the context of infectious diseases throughout life and the role of nutrition in optimizing treatment strategies. Nutrients. 2021;13(3):886. https://doi.org/10.3390/nu13030886
9. Belkaid Y, Hand TW. Role of the microbiota in immunity and inflammation. Cell. 2014;157(1):121-41. https://doi.org/10.1016/j.cell.2014.03.011
10. Miro-Blanch J, Yanes O. Epigenetic regulation at the interplay between gut microbiota and host metabolism. Front Genet. 2019;10:638. https://doi.org/10.3389/fgene.2019.00638
11. Ottman N, Smidt H, de Vos WM, Belzer C. The function of our microbiota: Who is out there and what do they do? Front Cell Infect Microbiol. 2012;2:104. https://doi.org/10.3389/fcimb.2012.00104
12. Nakamura YK, Metea C, Karstens L, Asquith M, Gruner H, Moscibrocki C, *et al.* Gut microbial alterations associated with protection from autoimmune uveitis. Invest Ophthalmol Vis Sci. 2016;57(7):3747-58. https://doi.org/10.1167/iovs.16-19733
13. Reid G, Gadir AA, Dhir R. Probiotics: Reiterating what they are and what they are not. Front Microbiol. 2019;10:424. https://doi.org/10.3389/fmicb.2019.00424
14. Wang ZB, Xin SS, Ding LN, Ding WY, Hou YL, Liu CQ, *et al.* The potential role of probiotics in controlling overweight/obesity and associated metabolic parameters in adults: A systematic review and meta-analysis. Evid Based Complement Alternat Med. 2019;2019:3862971. https://doi.org/10.1155/2019/3862971
15. Beserra BT, Fernandes R, do Rosario VA, Mocellin MC, Kuntz MGF, Trindade EBSM. A systematic review and meta-analysis of the prebiotics and synbiotics effects on glycaemia, insulin concentrations, and lipid parameters in adult patients with overweight or obesity. Clin Nutr. 2015;34(5):845-858. https://doi.org/10.1016/j.clnu.2014.10.004
16. Ayichew T, Belete A, Alebachew T, Tsehaye H, Berhanu H, Minwuyelet A. Bacterial probiotics: Their importance and limitations: A review. J Nutr Health Sci. 2017;4:202.
17. Hui W, Li T, Liu W, Zhou C, Gao F. Fecal microbiota transplantation for treatment of recurrent C. difficile infection: An updated randomized controlled trial meta-analysis. PLoS One. 2019;14(2):e0210016. https://doi.org/10.1371/journal.pone.0210016
18. Choi HH, Cho YS. Fecal microbiota transplantation: Current applications, effectiveness, and future perspectives. Clin Endosc. 2016;49(3):257-65. https://doi.org/10.5946/ce.2015.117
19. Riaz Rajoka MS, Shi J, Mehwish HM, Zhu J, Li Q, Shao D, *et al.* Interaction between diet composition and gut microbiota and its impact on gastrointestinal tract health. Food Sci Hum Wellness. 2017;6(3):121-30. https://doi.org/10.1016/j.fshw.2017.07.003
20. Finlay BB, Amato KR, Azad M, Blaser MJ, Bosch TC, Chu H, *et al.* Correction for Finlay *et al.*, the hygiene hypothesis, the COVID pandemic, and consequences for the human microbiome. Proc Natl Acad Sci U S A. 2021;118(6):118. https://doi.org/10.1073/pnas.2102333118
21. McCall LI, Callewaert C, Zhu Q, Song SJ, Bouslimani A, Minich JJ, *et al.* Home chemical and microbial transitions across urbanization. Nat Microbiol. 2020;5(1):108-15. https://doi.org/10.1038/s41564-019-0593-4
22. van den Elsen LW, Poyntz HC, Weyrich LS, Young W, Forbes-Blom EE. Embracing the gut microbiota: The new frontier for inflammatory and infectious diseases. Clin Transl Immunol. 2017;6(1):e125. https://doi.org/10.1038/cti.2016.91
23. Lazar V, Ditu LM, Pircalabioru GG, Gheorghe I, Curutiu C, Holban AM, *et al.* Aspects of gut microbiota and immune system interactions in infectious diseases, immunopathology, and cancer. Front Immunol.

2018;9:1830. https://doi.org/10.3389/fimmu.2018.01830
24. Slack E, Hapfelmeier S, Stecher B, Velykoredko Y, Stoel M, Lawson MAE, *et al.* Innate and adaptive immunity cooperate flexibly to maintain host-microbiota mutualism. Science. 2009;325(5940):617-20. https://doi.org/10.1126/science.1172747
25. Vineis P, Robinson O, Chadeau-Hyam M, Dehghan A, Mudway I, Dagnino S. What is new in the exposome? Environ Int. 2020;143:105887. https://doi.org/10.1016/j.envint.2020.105887
26. Libertucci J, Young VB. The role of the microbiota in infectious diseases. Nat Microbiol. 2019;4(1):35-45. https://doi.org/10.1038/s41564-018-0278-4
27. Lawley TD, Walker AW. Intestinal colonization resistance. Immunology. 2013;138(1):1-11. https://doi.org/10.1111/j.1365-2567.2012.03616.x
28. Chiu L, Bazin T, Truchetet ME, Schaeverbeke T, Delhaes L, Pradeu T. Protective microbiota: From localized to long-reaching co-immunity. Front Immunol. 2017;8:1678. https://doi.org/10.3389/fimmu.2017.01678
29. Thompson JA, Oliveira RA, Xavier KB. Chemical conversations in the gut microbiota. Gut Microbes. 2016;7(3):163-170. https://doi.org/10.1080/19490976.2016.1145374
30. Forgie AJ, Fouhse JM, Willing BP. Diet-microbe-host interactions that affect gut mucosal integrity and infection resistance. Front Immunol. 2019;10:1802. https://doi.org/10.3389/fimmu.2019.01802
31. Okumura R, Takeda K. Roles of intestinal epithelial cells in the maintenance of gut homeostasis. Exp Mol Med. 2017;49(5):e338. https://doi.org/10.1038/emm.2017.20
32. Hemarajata P, Versalovic J. Effects of probiotics on gut microbiota: Mechanisms of intestinal immunomodulation and neuromodulation. Ther Adv Gastroenterol. 2013;6(1):39-51. https://doi.org/10.1177/1756283X12459294
33. Davani-Davari D, Negahdaripour M, Karimzadeh I, Seifan M, Mohkam M, Masoumi SJ, *et al.* Prebiotics: Definition, types, sources, mechanisms, and clinical applications. Foods. 2019;8(3):92. https://doi.org/10.3390/foods8030092
34. Aziz T, Hussain N, Hameed Z, Lin L. Elucidating the role of diet in maintaining gut health to reduce the risk of obesity, cardiovascular and other age-related inflammatory diseases: Recent challenges and future recommendations. Gut Microbes. 2024;16(1):2297864. https://doi.org/10.1080/19490976.2023.2297864
35. Biazzo M, Deidda G. Fecal microbiota transplantation as a new therapeutic avenue for human diseases. J Clin Med. 2022;11(14):4119. https://doi.org/10.3390/jcm11144119
36. Mao YK, Kasper DL, Wang B, Forsythe P, Bienenstock J, Kunze WA. Bacteroides fragilis polysaccharide A is necessary and sufficient for acute activation of intestinal sensory neurons. Nat Commun. 2013;4:1465. https://doi.org/10.1038/ncomms2478
37. Knights D, Silverberg MS, Weersma RK, Gevers D, Dijkstra G, Huang H, *et al.* Complex host genetics influence the microbiome in inflammatory bowel disease. Genome Med. 2014;6:107. https://doi.org/10.1186/s13073-014-0107-1
38. Maynard CL, Elson CO, Hatton RD, Weaver CT. Reciprocal interactions of the intestinal microbiota and immune system. Nature. 2012;489(7415):231-241. https://doi.org/10.1038/nature11551
39. Liang D, Leung RK, Guan W, Au WW. Involvement of gut microbiome in human health and disease: Brief overview, knowledge gaps and research opportunities. Gut Pathog. 2018;10:3. https://doi.org/10.1186/s13099-018-0230-4
40. Human Microbiome Project Consortium. Structure, function and diversity of the healthy human microbiome. Nature. 2012;486(7402):207-214. https://doi.org/10.1038/nature11234
41. Perry RJ, Peng L, Barry NA, Cline GW, Zhang D, Cardone RL, *et al.* Acetate mediates a microbiome-brain-beta-cell axis to promote metabolic syndrome. Nature. 2016;534(7606):213-217. https://doi.org/10.1038/nature18309
42. Gulden E, Wong FS, Wen L. The gut microbiota and Type 1 Diabetes. Clin Immunol. 2015;159(2):143-153. https://doi.org/10.1016/j.clim.2015.05.013
43. Pop M, Walker AW, Paulson J, Lindsay B, Antonio M, Hossain MA, *et al.* Diarrhea in young children from low-income countries leads to large-scale alterations in intestinal microbiota composition. Genome Biol. 2014;15:R76. https://doi.org/10.1186/gb-2014-15-6-r76
44. Jalanka-Tuovinen J, Salojarvi J, Salonen A, Immonen O, Garsed K, Kelly FM, *et al.* Faecal microbiota composition and host-microbe cross-talk following gastroenteritis and in postinfectious irritable bowel syndrome. Gut. 2014;63(11):1737-1745. https://doi.org/10.1136/gutjnl-2013-305994
45. Manrique P, Dills M, Young MJ. The human gut phage community and its implications for health and disease. Viruses. 2017;9(6):141. https://doi.org/10.3390/v9060141
46. Pluznick JL, Protzko RJ, Gevorgyan H, Peterlin Z, Sipos A, Han J, *et al.* Olfactory receptor responding to gut microbiota-derived signals plays a role in renin secretion and blood pressure regulation. Proc Natl Acad Sci USA. 2013;110(11):4410-4415. https://doi.org/10.1073/pnas.1215927110
47. El Aidy S, Dinan TG, Cryan JF. Gut microbiota: The conductor in the orchestra of immune-neuroendocrine communication. Clin Ther. 2015;37(5):954-967. https://doi.org/10.1016/j.clinthera.2015.03.002
48. Gomez de Aguero M, Ganal-Vonarburg SC, Fuhrer T, Rupp S, Uchimura Y, Li H, *et al.* The maternal microbiota drives early postnatal innate immune development. Science. 2016;351(6279):1296-1302. https://doi.org/10.1126/science.aad2571
49. De Vadder F, Kovatcheva-Datchary P, Goncalves D, Vinera J, Zitoun C, Duchampt A, *et al.* Microbiota-generated metabolites promote metabolic benefits via gut-brain neural circuits. Cell. 2014;156(1-2):84-96. https://doi.org/10.1016/j.cell.2013.12.016
50. Rhee SH, Pothoulakis C, Mayer EA. Principles and clinical implications of the brain-gut-enteric microbiota axis. Nat Rev Gastroenterol Hepatol. 2009;6(5):306-314. https://doi.org/10.1038/nrgastro.2009.35
51. Deidda G, Biazzo M. Gut and brain: Investigating physiological and pathological interactions between microbiota and brain to gain new therapeutic avenues for brain diseases. Front Neurosci. 2021;15:753915. https://doi.org/10.3389/fnins.2021.753915
52. Gorski A, Miedzybrodzki R, Weber-Dabrowska B, Fortuna W, Letkiewicz S, Rogoz P, *et al.* Phage therapy:

Combating infections with potential for evolving from merely a treatment for complications to targeting diseases. Front Microbiol. 2016;7:1515. https://doi.org/10.3389/fmicb.2016.01515
53. Hyman P, Abedon ST. Bacteriophage host range and bacterial resistance. Adv Appl Microbiol. 2010;70:217-248. https://doi.org/10.1016/S0065-2164(10)70007-1
54. Chan BK, Abedon ST, Loc-Carrillo C. Phage cocktails and the future of phage therapy. Future Microbiol. 2013;8(6):769-783. https://doi.org/10.2217/fmb.13.47
55. Gupta R, Prasad Y. Efficacy of polyvalent bacteriophage P-27/HP to control multidrug resistant Staphylococcus aureus associated with human infections. Curr Microbiol. 2011;62(1):255-260. https://doi.org/10.1007/s00284-010-9699-x
56. Stratton CW. Dead bugs don't mutate: Susceptibility issues in the emergence of bacterial resistance. Emerg Infect Dis. 2003;9(1):10-16. https://doi.org/10.3201/eid0901.020172
57. Skurnik M, Pajunen M, Kiljunen S. Biotechnological challenges of phage therapy. Biotechnol Lett. 2007;29(7):995-1003. https://doi.org/10.1007/s10529-007-9346-1
58. Abedon ST, Thomas-Abedon C. Phage therapy pharmacology. Curr Pharm Biotechnol. 2010;11(1):28-47. https://doi.org/10.2174/138920110790725410
59. Dimidi E, Christodoulides S, Scott SM, Whelan K. Mechanisms of action of probiotics: A review. Front Microbiol. 2017;8:1452. https://doi.org/10.3389/fmicb.2017.01452
60. Collins S, Reid G. Distant site effects of ingested prebiotics. Nutrients. 2016;8(9):523. https://doi.org/10.3390/nu8090523
61. Louis P, Flint HJ, Michel C. How to manipulate the microbiota: Prebiotics. In: Schwab C, Gänzle MG, editors. Microbiota of the Human Body. Springer; 2016. p. 119-142.
62. Walker AW, Ince J, Duncan SH, Webster LM, Holtrop G, Ze X, *et al.* Dominant and diet-responsive groups of bacteria within the human colonic microbiota. ISME J. 2011;5(2):220-230. https://doi.org/10.1038/ismej.2010.118
63. Glenn G, Roberfroid M. Dietary modulation of the human colonic microbiota: Introducing the concept of prebiotics. J Nutr. 1995;125(6):1401-1414. https://doi.org/10.1093/jn/125.6.1401
64. Gibson GR, Probert HM, Van Loo J, Rastall RA, Roberfroid MB. Dietary modulation of the human colonic microbiota: Updating the concept of prebiotics
65. Nutr Res Rev. 2004;17(2):259-275. https://doi.org/10.1079/NRR200479
66. Bouhnik Y, Raskine L, Simoneau G, Vicaut E, Neut C, Flourié B, *et al.* The capacity of nondigestible carbohydrates to stimulate fecal bifidobacteria in healthy humans: A double-blind, randomized, placebo-controlled, parallel-group, dose-response relation study. Am J Clin Nutr. 2004;80(6):1658-1664. https://doi.org/10.1093/ajcn/80.6.1658
67. Flint HJ, Scott KP, Louis P, Duncan SH. The role of the gut microbiota in nutrition and health. Nat Rev Gastroenterol Hepatol. 2012;9(10):577-589. https://doi.org/10.1038/nrgastro.2012.156
68. Turroni F, Ventura M, Buttó LF, Duranti S, O'Toole PW, Motherway MOC, *et al.* Molecular dialogue between the human gut microbiota and the host: A lactobacillus and bifidobacterium perspective. Cell Mol Life Sci. 2014;71(1):183-203. https://doi.org/10.1007/s00018-013-1318-0
69. Roberfroid M. Health benefits of non-digestible oligosaccharides. In: Kritchevsky D, Bonfield C, editors. Dietary Fiber in Health and Disease. Springer; 1997. p. 211-219.
70. Morowvat MH, Nezafat N, Ghasemi Y, Zare MH, Mohkam M. Probiotic potential of five lactobacillus strains isolated from traditional Persian yoghurt in Fars Province, Iran: Viewing through the window of phylogenetics. Biosci Biotechnol Biochem. 2015;12(4):1265-1272.
71. Shokri D, Khorasgani MR, Mohkam M, Fatemi SM, Ghasemi Y, Taheri-Kafrani A. The inhibition effect of lactobacilli against growth and biofilm formation of Pseudomonas aeruginosa. Probiotics Antimicrob Proteins. 2018;10(1):34-42. https://doi.org/10.1007/s12602-017-9267-9
72. Stinson LF, Payne MS, Keelan JA. Planting the seed: Origins, composition, and postnatal health significance of the fetal gastrointestinal microbiota. Crit Rev Microbiol. 2017;43(3):352-369. https://doi.org/10.1080/1040841X.2016.1211088
73. Trompette A, Gollwitzer ES, Yadava K, Sichelstiel AK, Sprenger N, Ngom-Bru C, *et al.* Gut microbiota metabolism of dietary fiber influences allergic airway disease and hematopoiesis. Nat Med. 2014;20(2):159-166. https://doi.org/10.1038/nm.3444
74. Hernot DC, Boileau TW, Bauer LL, Middelbos IS, Murphy MR, Swanson KS, *et al. In vitro* fermentation profiles, gas production rates, and microbiota modulation as affected by certain fructans, galactooligosaccharides, and polydextrose. J Agric Food Chem. 2009;57(4):1354-1361. https://doi.org/10.1021/jf802484j
75. Zhou Z, Zhang Y, Zheng P, Chen X, Yang Y. Starch structure modulates metabolic activity and gut microbiota profile. Anaerobe. 2013;24:71-78. https://doi.org/10.1016/j.anaerobe.2013.09.012
76. Clarke TB, Davis KM, Lysenko ES, Zhou AY, Yu Y, Weiser JN. Recognition of peptidoglycan from the microbiota by NOD1 enhances systemic innate immunity. Nat Med. 2010;16(2):228-231. https://doi.org/10.1038/nm.2087
77. Hamer HM, Jonkers D, Venema K, Vanhoutvin S, Troost F, Brummer RJ. Review article: The role of butyrate on colonic function. Aliment Pharmacol Ther. 2008;27(2):104-119. https://doi.org/10.1111/j.1365-2036.2007.03562.x
78. den Besten G, van Eunen K, Groen AK, Venema K, Reijngoud DJ, Bakker BM. The role of short-chain fatty acids in the interplay between diet, gut microbiota, and host energy metabolism. J Lipid Res. 2013;54(9):2325-2340. https://doi.org/10.1194/jlr.R036012
79. Gibson GR, Scott KP, Rastall RA, Tuohy KM, Hotchkiss A, Dubert-Ferrandon A, *et al.* Dietary prebiotics: Current status and new definition. Food Sci Technol Bull Funct Foods. 2010;7(1):1-19. https://doi.org/10.1616/1476-2137.15880
80.